Onconetix, Inc. (Nasdaq: ONCO) and Ocuvex Therapeutics, Inc. have announced the execution of a definitive merger agreement, which has been approved by the boards of both companies. Under the agreement, Onconetix will acquire all outstanding equity interests of Ocuvex. Ocuvex equity holders will receive newly-issued Onconetix common stock, representing 90% of the combined company's equity. Onconetix shareholders will hold the remaining 10%. Post-merger, the Onconetix board will comprise seven directors, with five designated by Ocuvex and two by Onconetix. The transaction is expected to close in the fourth quarter of this year, subject to customary approvals. Anthony W. Amato, Chairman and CEO of Ocuvex, emphasized the benefits of accessing public capital markets to advance new treatment options. Andrew J. Oakley, Chairman of Onconetix, highlighted the value brought by Ocuvex's ophthalmic assets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.